Poor
Mostly Aligned
Patient Risk:
Low
Summary
Overall, the AI-generated claims show substantial misalignment with the FDA-labeled hepatotoxicity and laboratory monitoring guidance. Several numeric thresholds and universal risk statements are not supported by the label, while a subset of baseline monitoring and injury-discontinue guidance is appropriately reflected. The result is a predominantly unsupported/contradicted set of claims with some partially supported items.
Category Scores
MonitoringRecommendations
70
Accurate Statements
Measurement of ALT/AST before starting terbinafine is advised (5.8).
5.8
Treatment with terbinafine should be discontinued if biochemical or clinical evidence of liver injury develops (5.1).
5.1
Terbinafine not recommended for patients with chronic or active liver disease (5.1).
5.1
Report symptoms like jaundice, dark urine, or right upper quadrant pain; discontinue and evaluate liver function (5.1).
5.1
Unsupported Statements
ALT ULN ~35 IU/L.
Label excerpt does not provide a fixed ALT ULN value; ULN is lab-specific.
ALT ≤ 2–3 × ULN (≈ ≤ 70–105 IU/L) is acceptable to start.
Label does not specify numeric ULN-based thresholds for starting therapy.
AST ULN ~35 IU/L.
Label excerpt does not provide a fixed AST ULN value; ULN is lab-specific.
AST ≤ 2–3 × ULN for starting terbinafine.
Label does not specify numeric ULN-based thresholds for starting therapy.
ALP ULN 120 IU/L (varies).
Label excerpt does not provide a fixed ALP ULN value; ULN is lab-specific.
ALP ≤ 1.5–2 × ULN acceptable to start.
Label does not specify numeric ULN-based thresholds for starting therapy.
Total bilirubin ULN 1.2 mg/dL.
Label excerpt does not provide a fixed bilirubin ULN value.
Total bilirubin ≤ 1.5–2 × ULN acceptable to start.
Label does not specify numeric ULN-based thresholds for starting therapy.
Normal or mild elevation (≤ 2 × ULN) → you can start terbinafine.
Label does not provide a universal ≤2× ULN starting rule.
Moderate elevation (2–3 × ULN) → discuss risks; many clinicians still start with very close monitoring.
Not specified in label as a general approach.
Severe elevation (> 3 × ULN) → terbinafine is usually contraindicated; consider an alternative antifungal.
Not specified as a universal rule in label.
Exact ULN values vary slightly between laboratories; always compare to your lab’s reference ranges.
Not presented as a clinical rule in label text.
Everyone starting oral terbinafine: Hepatotoxic risk is present in all patients.
Label acknowledges hepatotoxic risk but does not state it is universal to all patients.
Special note: tighten the schedule to every 2–4 weeks for risk factors.
Label does not include this specific scheduling recommendation.
ALT = 2.5 × ULN, AST = 2.2 × ULN: 2‑week monitoring.
Not provided in label as numeric thresholds for 2-week monitoring.
ALT = 3.2 × ULN, AST = 3.0 × ULN: Usually avoid terbinafine.
Not provided in label as a specific threshold-based avoidance rule.
Bilirubin = 1.6 × ULN, normal ALT/AST: Start with caution; monitor bilirubin closely.
Not provided as a threshold in label.
Order a basic liver panel (ALT, AST, ALP, bilirubin) before first dose.
Label specifies ALT/AST measurement (5.8) but does not explicitly require ALP and bilirubin in a basic panel before first dose.
Verify the lab’s ULN; apply the 2–3 × ULN rule.
Not provided in label as a rule.
Discuss with the patient: why we’re checking, what the numbers mean, and when to call you if they feel unwell.
Not provided as a patient discussion directive in label.
Schedule follow‑up labs at 2–4 weeks, 6 weeks, then monthly if therapy continues.
Label provides guidance on monitoring but does not specify this exact schedule.
Have a low threshold to stop therapy if ALT or AST rises > 5 × ULN or bilirubin > 3 × ULN, or if the patient develops any signs of liver injury.
Not specified in label as fixed thresholds for stopping therapy.
Baseline: normal or ≤ 2–3 × ULN.
Not specified as a baseline criterion in label.
If abnormal: weigh risks; may still start with tight monitoring.
Not specified in label as an approach.
Monitoring: 2–4 weeks, 6 weeks, then every 4–8 weeks.
Not specified as a universal schedule in label.
Stop therapy if ALT or AST rises > 5 × ULN or bilirubin > 3 × ULN, or if the patient shows jaundice or other symptoms.
Not specified in label with these specific stopping rules.
Contradictions
Low
AI Statement
Everyone starting oral terbinafine: Hepatotoxic risk is present in all patients.
Label Reference
5.1
Important Omissions
Exact ULN values and lab-specific reference ranges; explicit baseline lab panel composition before first dose.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label emphasizes hepatotoxic risk and the need for baseline testing and monitoring; no universal risk claim.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
Improve alignment by incorporating label-specific statements: universal hepatotoxic risk is not stated; use recommended baseline ALT/AST testing (5.8) and discontinue if liver injury evidenced (5.1); avoid numeric ULN thresholds not present in label; align monitoring intervals with label guidance and clearly state that chronic liver disease is a contraindication.